Primary refractory diffuse large B cell lymphoma in the rituximab era

Current Opinion in Oncology

Volumn 27, Issue 5, 2015, Pages 377-383

  Sarkozy, Clémentine ^a   Coiffier, Bertrand ^a  

^a HOSPICES CIVILS DE LYON   (France)

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; Primary refractory; Rituximab

Indexed keywords

ANTHRACYCLINE; RITUXIMAB; TUMOR MARKER; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MYC PROTEIN; MYC PROTEIN, HUMAN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PATHOLOGIST; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DISEASE FREE SURVIVAL; DRUG EFFECTS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; PROGNOSIS; PROTO ONCOGENE; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; GENES, BCL-1; GENES, BCL-2; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; RITUXIMAB; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84942583381     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000209     Document Type: Review

References (53)

1. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma Tumori 2002 88, S26-S28.
2. Habermann TM, Weller EA, Morriso n VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:3121-3127.
3. Pfreundschuh M, Kuhnt E, Trum per L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Onc ol 2011; 12:1013-1022.
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105-116.
5. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improve d outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027-5033.
6. Larouche J, Berger F, Chassagne-Clement C, et al. Lymphoma recurrence 5 years or later followin g diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 2010; 28:2094-2100.
7. Tarella C, Gueli A, Delaini F, et al. Rate of primary refractory disease in B and T-Cell non-Hodgkin's Lymphoma: correlation with long-term survival. PLoS One 2014; 9:e106745. Long-term survival in non-Hodgki n lymphoma is highly dependent on chemosensitivity and response to first-line strategy.
8. Philip T, Chauvin F, Armitage JO, et al. PARMA international protocol: pilot study of DHAP followed by involved field radioth erapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77:1587-1592.
9. Mounier N, Canals C, Gisselbrecht C, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2012; 18:788-793.
10. Sie niawski M, Staak O, Glossmann JP, et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol 2007; 86:107-115.
11. Coiffier B. Rituximab in the treatment of diffuse large B-Cell lymphomas. Semin Oncol 2002; 29:30-35.
12. Coiffier B. Rituximab t herapy in malignant lymphoma. Oncogene 2007; 26:3603-3613.
13. Maurer MJ, Ghesquié res H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse la rge B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2014; 32:1066-1073. Patients with DLBCL who achieve disease-free survival after 24 months of followup have a subsequent overall survival equivalent to that of the age-An d sexmatched general population.
14. Rovira J, Valera A, Colomo L, et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunoche motherapy. Ann Hematol 2015; 94:803-812. Rituximab did not markedly improve the overall survival of refractory patients.
15. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-1947.
16. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74.
17. Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29:4079-4087.
18. Petrich AM, Nabhan C, Smith SM. MYC-Associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer 2014; 120:3884-3895.
19. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. JClinOncol 2012; 30:3452-3459.
20. Hu S, Xu-Monette Z, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Co nsortium Program. Blood 2013; 121:4021-4031.
21. Song MK, Chung JS, Lee JJ, et al. High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. Int J Hematol 2015; 1 01:140-147.
22. Huang X, Meng B, Iqbal J, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with RCHOP. J Clin Oncol 2013; 31:4520-4528.
23. Zheng RL, Jiang YJ, Wang X. Role of micrornas on therapy resistance in nonhodgkin's lymphoma. Int J Clin Exp Med 2014; 7:3818-3832.
24. Li C, Thompson MA, Tamayo AT, et al. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget Oncotarget 2012; 3:314-326.
25. Mishima Y, Terui Y, Takeuchi K, et al. The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J 2011; 1:e15.
26. Kawano R, Karube K, Kikuchi M, et al. Oncogene associated cDNA microarray analysis shows PRAME gene expression is a marker for response to anthracycline containing chemotherapy in patients with diffuse large B-cell lympho ma. J Clin Exp Hematop 2009; 49:1-7.
27. Maxwell SA, Li Z, Jaya D, et al. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009; 284:22379-22389.
28. Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximabcontaining chemo-immunotherapy in diffuse large B cell lymphoma does not predict fut ility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20:1729-1736. Patients with early relapse (within a year) might benefit from an intensive treatment with ASCT despite a higher risk of treatme nt failure and mortality in the first 9 months from ASCT compared to late-relapsing patients.
29. Alici S, Bavbek S, Basaran M, Onat H. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without com plete response to first-line therapy. Adv Ther 2006; 23:534-542.
30. Villela L, Lopez-Guillermo A, Montoto S, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001; 91: 1557-1562.
31. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggres sive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16:3264-3269.
32. Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+ ) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30:4462-4469.
33. Chen YB, Hochberg EP, Feng Y, et al. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone ther apy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:789-796.
34. Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111:537-543.
35. Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 2012; 53:836-841.
36. Atta J, Chow KU, Weidmann E, et al. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2007; 48:349-356.
37. Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymp homa. Leuk Lymphoma 2008; 49:1329-1336.
38. Aribi M, Mesli N, Remla N, et al. Gemcitabine and treatment of diffuse large Bcell lymphoma in relapsed or refractory elderly patients: a prospective r andomized trial in Algeria. J Cancer Res Ther 2010; 6:41-46.
39. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as secondline therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103:3684-3688.
40. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refrac tory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008; 93:1829-1836.
41. Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16:3264-3269.
42. Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose che moradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96:2399-2404.
43. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006; 38:211-216.
44. Elstrom RL, Marti n P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clin Lymphoma Myeloma Leuk 2010; 10:192-196.
45. Chen CI, Roitman D, Tsang R, et al. ' Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and re fractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30:885-891.
46. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warrante d in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 2005; 130:363-372.
47. Gisselbrecht C, Glass B, Mounier N, et al. Salv age regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:4184-4190.
48. Hamadani M,Saber W,Ahn KW,et al. Impact of pretransp lantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large b cell lymphoma and grade iii follicular lymphoma Blood Marrow Transplant 2013 19 746-753.
49. Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-l abel, randomised, phase 2 trial. Lancet Oncol 2014; 15:757-766. In this randomised trial, investigating the effect of adding rituximab to standard prophylaxis for graft-versus-host disease after transplantation, patients with a primary refractory DLB CL or relapsing after ASCT were included. The overall survival at 1 year for the whole study population was 52% and there was no benefit due to rituximab on the incidence of GVHD.
50. Lazarus HM, Zhang MJ, Carreras J, et a l. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse largeBcell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2010; 16:35-45.
51. Younes A. Be yond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8:85-96.
52. Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cycloph osphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a nonrandomised, phase 1b study. Lancet Oncol 2014; 15:1019-1026. Ibrutinib, a new BTK inhibito r, is well tolerated when added to the classical R-CHOP regimen. The association could improve the outcome of patient, but this needs to be confirmed in a randomized trial.
53. Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21:723-737.